Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers
Technology in Cancer Research & Treatment · 2023
DOI: 10.1177/15330338221145992 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Yingshu Cui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Immunoconjugates, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Worldwide, the incidence rate of breast cancer is the highest in women. Approximately 2.3 million people were newly diagnosed and 0.685 million were dead of breast cancer in 2020, which continues to grow. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with a higher risk of recurrence and metastasis, but disappointly, there are no effective and specific therapies clinically, especially for patients presenting with metastatic diseases. Therefore, it is urgent to develop a new type of cancer therapy for survival improvisation and adverse effects alleviation of breast cancers. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed, photochemistry-based cancer therapy. It was drive by an antibody–photoabsorber conjugate (APC) which is triggered by near-infrared light. The key part of APC is a cancer-targeting monoclonal antibody (mAb) that can bind to receptors or antigens on the surface of tumor cells. Because of this targeted conjugate accumulation, subsequent deployment of focal NIR-light results in functional damage on the targeted cell membranes without harming the immediately adjacent receptor-negative cells and evokes a kind of photochemical, speedy, and highly specific immunogenic cell death (ICD) of cancer cells with corresponding antigens. Subsequently, immature dendritic cells adjacent to dying cancer cells will become mature, further inducing a host-oriented anti-cancer immune response, complicatedly and comprehensively. Currently, NIR-PIT has progressed into phase 3 clinical trial for recurrent head and neck cancer. And preclinical studies have illustrated strong therapeutic efficacy of NIR-PIT targeting various molecular receptors overexpressed in breast cancer cells, including EGFR, HER2, CD44c, CD206, ICAM-1 and FAP-α. Thereby, NIR-PIT is in early trials, but appears to be a promising breast cancer therapy and moving into the future. Here, we present the specific advantages and discuss the most recent preclinical studies against several transmembrane proteins of NIR-PIT in breast cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
- Medical School of Chinese PLA, Beijing, China.
- Department of Laser, the First Medical Center, 104607Chinese PLA General Hospital, Beijing, China.
- Department of Oncology, the Seventh Medical Center, Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Yingshu Cui, Xiaosong Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cui, Y., Xu, Y., Li, Y., Sun, Y., Hu, J., Jia, J., & Li, X. (2023). Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338221145992
Vancouver
Cui Y, Xu Y, Li Y, Sun Y, Hu J, Jia J, et al. Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338221145992
BibTeX
@article{Cui2023,
author = {Cui, Yingshu and Xu, Yuanyuan and Li, Yi and Sun, Yuanyuan and Hu, Jia and Jia, Jia and Li, Xiaosong},
title = {Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers},
journal = {Technology in Cancer Research & Treatment},
year = {2023},
doi = {10.1177/15330338221145992}
}
EUVIMED